丙酸氟替卡松、孟鲁斯特钠、酮替芬不同联用方案治疗儿童咳嗽变异性哮喘的临床比较

董继军; 杨明刚; 李冰

doi:10.13407/j.cnki.jpp.1672-108X.2020.03.006

您当前的位置：

首页 >

文章列表页 >

丙酸氟替卡松、孟鲁斯特钠、酮替芬不同联用方案治疗儿童咳嗽变异性哮喘的临床比较

论著（儿科药物治疗学） | 更新时间：2022-11-03

- 丙酸氟替卡松、孟鲁斯特钠、酮替芬不同联用方案治疗儿童咳嗽变异性哮喘的临床比较
- Clinical Comparison of Fluticasone Propionate, Montelukast Sodium and Ketotifen in Different Combination Regimens in the Treatment of Cough Variant Asthma in Children
- 儿科药学杂志 2020年26卷第3期页码：18-21
- 作者机构：
  
  荆州市妇幼保健院,湖北,荆州,434020
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.03.006
  中图分类号：
- 纸质出版日期：2020，
  
  网络出版日期：2020-3-10，
扫描看全文
董继军, 杨明刚, 李冰. 丙酸氟替卡松、孟鲁斯特钠、酮替芬不同联用方案治疗儿童咳嗽变异性哮喘的临床比较[J]. 儿科药学杂志, 2020,26(3):18-21.

Dong Jijun, Yang Minggang, Li Bing. Clinical Comparison of Fluticasone Propionate, Montelukast Sodium and Ketotifen in Different Combination Regimens in the Treatment of Cough Variant Asthma in Children[J]. 2020,26(3):18-21.
董继军, 杨明刚, 李冰. 丙酸氟替卡松、孟鲁斯特钠、酮替芬不同联用方案治疗儿童咳嗽变异性哮喘的临床比较[J]. 儿科药学杂志, 2020,26(3):18-21. DOI： 10.13407/j.cnki.jpp.1672-108X.2020.03.006.

Dong Jijun, Yang Minggang, Li Bing. Clinical Comparison of Fluticasone Propionate, Montelukast Sodium and Ketotifen in Different Combination Regimens in the Treatment of Cough Variant Asthma in Children[J]. 2020,26(3):18-21. DOI： 10.13407/j.cnki.jpp.1672-108X.2020.03.006.

摘要

目的：探讨丙酸氟替卡松（Flu）、孟鲁斯特钠（Mon）、酮替芬（Ket）三种药物不同联合用药方案治疗咳嗽变异性哮喘（CVA）的临床效果。方法：选取2016年6月至2018年6月我院就诊的245例CVA患儿为研究对象，采用随机数字表法将245例患儿随机分为Flu组、Mon组、Ket组、Flu+Mon组、Flu+Ket组、Mon+Ket组、Flu+Mon+Ket组7组，每组各35例，治疗8周及12周后进行效果评价，评价指标包括肺功能指标（FEV1%、PEF%）、咳嗽症状评分、不良反应发生情况及咳嗽复发情况。结果：治疗8周后，各组患儿肺功能指标（FEV1%、PEF%）均有所改善，咳嗽症状评分均有所降低，三种药物联合用药均优于单种药物及两种药物联合应用。治疗12周后，除Ket组外，其他组别患儿肺功能指标（FEV1%、PEF%）及咳嗽症状评分差异不明显。不良反应发生率监测显示，联合用药并不增加不良反应发生率。咳嗽复发率监测显示，Ket组患儿咳嗽复发率明显高于其他组（P<0.05）。结论：本研究认为，Flu、Mon、Ket三种药物均可用于儿童咳嗽变异性哮喘的治疗，用药方案为治疗前8周，推荐三种药物联合应用，可获得最佳的治疗效果；8~12周，推荐Flu或Mon单独用药，可获得与三种药物联合用药相似的治疗效果，但不推荐单独使用Ket

Abstract

Objective: To investigate the clinical effects of fluticasone propionate (Flu)

montelukast sodium (Mon) and ketotifen (Ket) in the treatment of cough variant asthma (CVA) in Children. Methods: Totally 245 patients with CVA admitted into our hospital from Jun. 2016 to Jun. 2018 were extracted to be divided into the Flu group

Mon group

Ket group

Flu+Mon group

Flu+Ket group

Mon+Ket group and Flu+Mon+Ket group via the random number table

with 35 cases in each group. The effects were evaluated after 8 weeks and 12 weeks of treatment. The evaluation indexes mainly included lung function (FEV1%

PEF%)

cough symptom score

adverse drug reactions and recurrence of cough. Results: After 8 weeks of treatment

the lung function index (FEV1%

PEF%) of each group was improved

the cough symptom score was decreased

and the combination of three drugs was superior to the single drug and the combination of two drugs. After 12 weeks of treatment

except for the Ket group

there were no significant differences in lung function index (FEV1%

PEF%) and cough symptom score among other groups. Adverse drug reactions monitoring showed that drug combination did not increase the incidence of adverse drug reactions. The recurrence rate of cough in children in the Ket group was significantly higher than that in the other groups (P<0.05). Conclusion: This study indicates that Flu

Mon and Ket can be used in the treatment of CVA in children. The recommended regimen is: in the first 8 weeks

the combination of three drugs can obtain the best therapeutic effects. From 8 to 12 weeks

Flu or Mon alone can achieve similar therapeutic effects as the combination of three drugs

but Ket alone is not recommended.

关键词

咳嗽变异性哮喘联合用药儿童临床效果

Keywords

cough variant asthmarug combinationchildrenclinical effects

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

伏立康唑血药浓度监测在儿童血液病的临床应用

某三甲综合医院36 例儿童药物误服中毒病例分析及药学服务思考

右美托咪定与氢吗啡酮复合滴鼻在腺样体手术患儿术前母婴分离镇静中的应用

西罗莫司治疗儿童蓝色橡皮疱痣综合征5 例并文献复习

唑来膦酸用于儿童代谢性骨疾病有效性和安全性的系统评价